Activation of the TLR3/NF-κB pathway significantly upregulated MHC-I gene expression, thereby inhibiting immune escape and augmenting immunotherapy in muscle-invasive bladder cancer. The gene discussed is NFKB1; the disease is urinary bladder carcinoma.